PepDiana
Back to Primary literature
Primary-literature peptidehigh evidence

PEPDIA-PLP-001878

C1

Aliases: C1

FASTA CSV JSON

Normalized sequence

LQYPDDSDDE

10 amino acids

Release PepDiana-V1-20260620

17

Activity records

1

Source papers

16

Positive

1

Negative / threshold

Versioned scientific descriptors

Physicochemical properties and standard representations

calculated sequence and structure

Reported properties

No separate physicochemical property was reported in the primary-literature identity record. PepDiana release values are shown as computed properties.

Computed properties

physchem-20260620

Molecular weight

1196.1314 Da

Molecular formula

C49H69N11O24

Theoretical pI

4.05

Net charge at pH 7

-5.2284

GRAVY

-2.09

Instability index

58.12

Aromaticity

0.1

Topological polar surface area

586.48 Ų

cLogP

-6.7165

Hydrogen-bond donors

18

Hydrogen-bond acceptors

19

Rotatable bonds

37

Method: PepDiana sequence/structure descriptor pipeline

Tool: Biopython+RDKit · Biopython 1.85; RDKit 2024.09.6

Calculated: 2026-06-20T11:01:38.358971+00:00

Assumptions: ph=7; termini=free N-terminus and free C-terminus for simple linear peptides; stereochemistry=standard L-amino acids; smiles_length_limit=200

Sequence representations

representations-20260620

ProForma 2.0

validated simple linear

LQYPDDSDDE

HELM 2.0

validated simple linear

PEPTIDE1{L.Q.Y.P.D.D.S.D.D.E}$$$$V2.0

Canonical SMILES

validated

CC(C)CC(N)C(=O)NC(CCC(N)=O)C(=O)NC(Cc1ccc(O)cc1)C(=O)N1CCCC1C(=O)NC(CC(=O)O)C(=O)NC(CC(=O)O)C(=O)NC(CO)C(=O)NC(CC(=O)O)C(=O)NC(CC(=O)O)C(=O)NC(CCC(=O)O)C(=O)O

Isomeric SMILES

validated

CC(C)C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)O

Paper-level observations

Experimental evidence grouped by activity

Antiviral 16 records

PMC12182627

16 observations
AntiviralAnti-HSVPositive observation
Record detail

In the viral inactivation assay, peptide C1 at 250 µg/mL reduced HSV-1 ... infections by 64.92% ... with IC 50 values of 109.9 ... µg/mL

Mention PMC12182627::PEP000001PMC12182627text
Measure
IC50
Value
109.9 µg/mL
Target
Vero
Assay
Viral inactivation assay
Source publication
AntiviralAnti-HSVPositive observation
Record detail

In the viral inactivation assay, peptide C1 at 250 µg/mL reduced ... HSV-2 infections by ... 67.16%, respectively, with IC 50 values of ... 111.13 µg/mL

Mention PMC12182627::PEP000001PMC12182627text
Measure
IC50
Value
111.13 µg/mL
Target
Vero
Assay
Viral inactivation assay
Source publication
AntiviralAnti-HSVPositive observation
Record detail

Peptide C1 offered 62.03% protection against HSV-1 and 59.38% protection against HSV-2 infections at 250 µg/mL in the viral attachment inhibition assay.

Mention PMC12182627::PEP000001PMC12182627text
Measure
percent_inhibition
Value
62.03%
Target
Vero
Assay
Viral attachment inhibition assay
Source publication
AntiviralAnti-HSVPositive observation
Record detail

Peptide C1 offered 62.03% protection against HSV-1 and 59.38% protection against HSV-2 infections at 250 µg/mL in the viral attachment inhibition assay.

Mention PMC12182627::PEP000001PMC12182627text
Measure
percent_inhibition
Value
59.38%
Target
Vero
Assay
Viral attachment inhibition assay
Source publication
AntiviralAnti-HSVPositive observation
Record detail

Moreover, peptide C1 showed better protection (HSV-1: 71.37%, HSV-2: 76.28%) in viral entry inhibition assay at 250 µg/mL concentration.

Mention PMC12182627::PEP000001PMC12182627text
Measure
percent_inhibition
Value
71.37%
Target
Vero
Assay
Viral entry inhibition assay
Source publication
AntiviralAnti-HSVPositive observation
Record detail

Moreover, peptide C1 showed better protection (HSV-1: 71.37%, HSV-2: 76.28%) in viral entry inhibition assay at 250 µg/mL concentration.

Mention PMC12182627::PEP000001PMC12182627text
Measure
percent_inhibition
Value
76.28%
Target
Vero
Assay
Viral entry inhibition assay
Source publication
AntiviralAnti-HSVPositive observation
Record detail

at the highest concentration (250 µg/mL), peptide C1 demonstrated 49.37% ... protection against HSV-1 ... in the CPE inhibition assay

Mention PMC12182627::PEP000001PMC12182627text
Measure
percent_inhibition
Value
49.37%
Target
Vero
Assay
Cytopathic effect (CPE) inhibition assay
Source publication
AntiviralAnti-HSVPositive observation
Record detail

at the highest concentration (250 µg/mL), peptide C1 demonstrated ... 48.99% protection against ... HSV-2 in the CPE inhibition assay

Mention PMC12182627::PEP000001PMC12182627text
Measure
percent_inhibition
Value
48.99%
Target
Vero
Assay
Cytopathic effect (CPE) inhibition assay
Source publication
Toxicity 1 records

PMC12182627

1 observations
ToxicityCytotoxicNegative / threshold
Record detail

Cell viability of 91.74% ... at 250 µg/mL peptide concentration, respectively ( Figure S5 ) for C1. Both peptides were nontoxic to Vero cells at all the concentrations of 15.62 - 250 µg/mL.

Mention PMC12182627::PEP000001PMC12182627text
Measure
cell_viability
Value
91.74%
Target
Cercopithecus aethiops
Assay
MTT assay
Source publication

Citation and release provenance

Cite this identity as PepDiana record PEPDIA-PLP-001878, release PepDiana-V1-20260620. Experimental observations retain their paper, mention, and activity-record identifiers.

Record updated: 2026-06-22T07:14:26.229247+00:00